 Neoplasm Invasiveness
"Neoplasm Invasiveness" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
| Descriptor ID |
D009361
|
| MeSH Number(s) |
C04.697.645 C23.550.727.645
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Invasiveness".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Invasiveness".
This graph shows the total number of publications written about "Neoplasm Invasiveness" by people in this website by year, and whether "Neoplasm Invasiveness" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 3 | 5 | | 1997 | 0 | 3 | 3 | | 1998 | 0 | 5 | 5 | | 1999 | 1 | 1 | 2 | | 2000 | 0 | 8 | 8 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 6 | 6 | | 2004 | 2 | 7 | 9 | | 2005 | 0 | 10 | 10 | | 2006 | 3 | 9 | 12 | | 2007 | 0 | 9 | 9 | | 2008 | 1 | 13 | 14 | | 2009 | 2 | 15 | 17 | | 2010 | 1 | 14 | 15 | | 2011 | 1 | 18 | 19 | | 2012 | 1 | 21 | 22 | | 2013 | 0 | 21 | 21 | | 2014 | 0 | 18 | 18 | | 2015 | 1 | 17 | 18 | | 2016 | 1 | 23 | 24 | | 2017 | 0 | 27 | 27 | | 2018 | 1 | 15 | 16 | | 2019 | 1 | 17 | 18 | | 2020 | 0 | 15 | 15 | | 2021 | 1 | 1 | 2 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 3 | 3 | | 2024 | 3 | 8 | 11 | | 2025 | 0 | 6 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Invasiveness" by people in Profiles.
-
Musso G, Garofano G, Dabbas M, Meagher MF, Yuen KL, Birouty N, Baker B, Saitta C, Guer M, Montorsi F, Briganti A, Capitanio U, Larcher A, Salonia A, Derweesh IH. The Influence of Lymphovascular Invasion on T Stage Upstaging and Overall Survival in Renal Cell Carcinoma: A Population-Based Study. Clin Genitourin Cancer. 2025 Oct; 23(5):102412.
-
Tiago M, Purwin TJ, Stefanski CD, da Silva RO, Fane ME, Chhabra Y, Haj JI, Teh JL, Kadamb R, Cai W, Rosenbaum SR, Chua V, Hacohen N, Davies MA, Villanueva J, Chervoneva I, Weeraratna AT, Erkes DA, Capparelli C, Aguirre-Ghiso JA, Aplin AE. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. J Clin Invest. 2025 Sep 16; 135(18).
-
Kawashima J, Akabane M, Woldesenbet S, Tsilimigras DI, Endo Y, Sahara K, Cauchy F, Aucejo F, Marques HP, Lopes R, Rodriguea A, Hugh T, Shen F, Maithel SK, Groot Koerkamp B, Popescu I, Kitago M, Weiss MJ, Martel G, Pulitano C, Aldrighetti L, Poultsides G, Ruzzente A, Bauer TW, Gleisner A, Endo I, Pawlik TM. Oncological Resectability Criteria for Intrahepatic Cholangiocarcinoma: A Preoperative Framework for Multidisciplinary Management. Ann Surg Oncol. 2025 Oct; 32(10):7141-7151.
-
Tran AT, Wisniewski EO, Mistriotis P, Stoletov K, Parlani M, Amitrano A, Ifemembi B, Lee SJ, Bera K, Zhang Y, Tuntithavornwat S, Afthinos A, Kiepas A, Agarwal B, Nath S, Jamieson JJ, Zuo Y, Habib D, Wu PH, Martin SS, Gerecht S, Gu L, Lewis JD, Kalab P, Friedl P, Konstantopoulos K. Cytoplasmic anillin and Ect2 promote RhoA/myosin II-dependent confined migration and invasion. Nat Mater. 2025 Sep; 24(9):1476-1488.
-
Akabane M, Kawashima J, Woldesenbet S, Lee GR, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Distinct patterns of late recurrence in long-term hepatocellular carcinoma survivors. J Gastrointest Surg. 2025 Sep; 29(9):102135.
-
Ishida H, Stoop TF, Oba A, Bachellier P, Ban D, Endo I, Franklin O, Fujii T, Gulla A, Hackert T, Halimi A, Hirano S, Jang JY, Katz MHG, Maekawa A, Nealon WH, Perri G, Ramia JM, Rompen IF, Satoi S, Schulick RD, Shrikhande SV, Tsung A, Wolfgang CL, Besselink MG, Del Chiaro M. Global survey on surgeon preference and current practice for pancreatic neck and body cancer with portomesenteric venous involvement. HPB (Oxford). 2025 Jul; 27(7):910-921.
-
Boulton DP, Hughes CJ, Vaira V, Del Gobbo A, Palleschi A, Locatelli M, Danis E, Raza M, Neumann AJ, Purdy SC, Lerma R, Meshki J, Ford HL, Prekeris R, Morrissey C, Caino MC. MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity. Cell Rep. 2025 01 28; 44(1):115120.
-
Iyer G, Tangen CM, Sarfaty M, Regazzi AM, Lee IL, Fong M, Choi W, Dinney CPN, Flaig TW, Thompson IM, Lerner SP, McConkey DJ, Rosenberg JE. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. 2024 Nov; 8:e2400287.
-
Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, Schuckman A, Sagalowsky AI, Smith ND, Kamat AM, Kassouf W, Plets M, Bangs R, Koppie TM, Alva A, La Rosa FG, Pal SK, Kibel AS, Canter DJ, Thompson IM. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.
-
Kuo LW, Crump LS, O'Neill K, Williams MM, Christenson JL, Spoelstra NS, Roy MK, Argabright A, Reisz JA, D'Alessandro A, Boorgula MP, Goodspeed A, Bickerdike M, Bitler BG, Richer JK. Blocking Tryptophan Catabolism Reduces Triple-Negative Breast Cancer Invasive Capacity. Cancer Res Commun. 2024 10 01; 4(10):2699-2713.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|